Floatz logo

Amivantamab-Vmjw

Malignant Primary Gliomas

Institute of Cancer Research, United Kingdommonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

108 Active assets in the Malignant Primary Gliomas cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Amivantamab-Vmjw is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →